Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW


On October 19, 2016, the U.S. Food and Drug Administration (FDA) approved Lartruvo (ocaratumab) in combination with doxorubicin for the treatment of patients who cannot be cured by radiation therapy and surgery, but whose histological classification is suitable for the use of anthracyclines. Advanced soft tissue sarcoma (STS) in adults.